[Treatment of chronic hepatitis C in special groups].
Bourlière
Marc
M
Service d'hépato-gastroentérologie, Fondation Hôpital Saint-Joseph, Marseille.
Halfon
Philippe
P
Portal
Isabelle
I
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation; D016031:Liver Transplantation; D001523:Mental Disorders / Q000150:complications*; D006435:Renal Dialysis; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013789:Thalassemia / Q000150:complications* / Q000628:therapy; D013997:Time Factors
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin